Fracturas vertebrales múltiples tras la suspensión de tratamiento con denosumab: serie de diez casos
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Reumatología Clínica
- Vol. 16 (6) , 480-484
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTSBone, 2017
- Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)Bone, 2017
- Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional CasesJournal of Bone and Mineral Research, 2017
- Observations following discontinuation of long-term denosumab therapyOsteoporosis International, 2017
- Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases ReportThe Journal of Clinical Endocrinology & Metabolism, 2016
- Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanicsOsteoporosis International, 2015
- Denosumab for the treatment of osteoporosisExpert Opinion on Drug Metabolism & Toxicology, 2014
- Denosumab for the treatment of osteoporosis: A systematic literature reviewReumatología Clínica, 2013
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) TrialJournal of Bone and Mineral Research, 2012
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009